iRhythm Holdings Inc. (NASDAQ: IRTC) reported an insider sale that reduced the company stock holdings of Chief Financial Officer Daniel G. Wilson. According to a Form 4 filed with the Securities and Exchange Commission, Wilson sold 5,188 shares of common stock on February 25, 2026, at a price of $135.42 per share, producing total gross proceeds of $702,553.
The sale took place while the shares were trading at $140.18, and the stock has shown notable short-term weakness, declining 7% over the past week and falling 21% year-to-date, as reported in market data.
In a related transaction disclosed in the same Form 4 filing, Wilson acquired 9,412 shares of iRhythm stock on February 24, 2026, at no cost. Those shares were issued after the Compensation & Human Capital Management Committee of the Board of Directors of the Issuer determined that the performance conditions were met for performance Restricted Stock Units that had been granted to Wilson on February 27, 2023.
Following these transactions, Wilson's direct ownership stands at 30,694 shares of iRhythm. He also holds an additional 100 shares indirectly through a Family Trust, according to the filing.
Market commentary included in the regulatory and research landscape points to divergent signals for the company. InvestingPro's analysis has placed the stock on its Most Overvalued list, indicating the shares appear to trade above the platform's assessment of Fair Value. Investors are able to access more extensive coverage through a Pro Research Report on IRTC for additional context.
On the operational side, iRhythm Technologies reported fourth-quarter revenue of $208.9 million, a 27.1% increase year-over-year, and beat consensus estimates by approximately 4%. The company also reported positive GAAP net income for the first time, a notable accounting milestone highlighted in recent company disclosures.
Sell-side reaction to the quarter has been mixed. Truist Securities and Canaccord Genuity each trimmed their price targets to $200 and $198, respectively, while maintaining Buy ratings and explicitly citing valuation concerns as the reason for the reduced targets. Morgan Stanley reiterated an Overweight rating with a $205 price target and noted the company's strong fourth-quarter performance.
Looking ahead, iRhythm said it expects to exceed its previously stated revenue guidance for 2025, attributing that outlook to record unit volume. The company has also provided a financial framework for 2026: it forecasts revenue growth of 17% to 18%, translating to a revenue range of $870 million to $880 million, and anticipates an adjusted EBITDA margin in the vicinity of 11.5% to 12.5% for the year.
These filings and disclosures offer a combination of executive-level portfolio activity, analyst reassessments, and updated company guidance for investors to weigh. The insider sale and concurrent issuance of performance-based shares underscore the interplay between compensation mechanics and executive stock transactions, while the company's reported results and updated outlook provide the operative financial context contained in recent filings and research notes.